Corbus Pharmaceuticals Holdings (CRBP) Current Deferred Revenue (2015 - 2020)

Corbus Pharmaceuticals Holdings' Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $270530.0 for Q2 2020.

• On a quarterly basis, Current Deferred Revenue fell 89.1% year-over-year to $270530.0 in Q2 2020; TTM through Jun 2020 was $270530.0, a 89.1% decrease from a year earlier, with the FY2018 full-year figure at $35996.0, changed N/A from the prior year.
• Current Deferred Revenue declined to $270530.0 in Q2 2020 per CRBP's latest filing, from $2.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $27.0 million in Q1 2019 and bottomed at $12866.0 in Q2 2017.
• The 5-year median for Current Deferred Revenue is $1.4 million (2016), against an average of $3.7 million.
• Across the five-year window, Current Deferred Revenue plunged 98.78% in 2017 and surged 34725.8% in 2018, its largest moves.
• Year by year, Current Deferred Revenue stood at $1.9 million in 2016, then tumbled by 99.34% to $12866.0 in 2017, then soared by 179.78% to $35996.0 in 2018, then soared by 6795.87% to $2.5 million in 2019, then slumped by 89.1% to $270530.0 in 2020.
• Per Business Quant, the three latest CRBP Current Deferred Revenue figures stand at $270530.0 (Q2 2020), $2.5 million (Q2 2019), and $27.0 million (Q1 2019).